A phase IV cohort study to assess the feasibility of substituting double ritonavir-boosted protease inhibitors (PI) with ritonavir-boosted darunavir (DRV/r) in HIV-infected individuals with viral suppression on highly active antiretroviral therapy (HAART)

Trial Profile

A phase IV cohort study to assess the feasibility of substituting double ritonavir-boosted protease inhibitors (PI) with ritonavir-boosted darunavir (DRV/r) in HIV-infected individuals with viral suppression on highly active antiretroviral therapy (HAART)

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Nov 2012

At a glance

  • Drugs Darunavir (Primary) ; Ritonavir
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Aug 2010 Actual patient number (12) added as reported by ClinicalTrials.gov.
    • 13 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top